ReviewThe Kaohsiung journal of medical sciences2025
Non-Invasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features (NIFTPs).
Review in The Kaohsiung journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic impact of RAS mutation on papillary thyroid carcinoma: a systematic review and meta-analysis.Thyroid research · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past few years, follicular-patterned thyroid nodules with nuclear features of papillary thyroid carcinoma (PTC) have been further subclassified based on molecular profiling, histologic features, and clinical behavior. Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTPs) was established as a distinct entity in the 2017 4th edition of the WHO Classification of Tumors of Endocrine Organs due to its indolent clinical behavior and excellent prognosis. These tumors are characterized by a well-defined border, an exclusive follicular growth pattern, and PTC nuclear features. Molecularly, NIFTPs typically harbor RAS gene mutations, PAX8-PPARG rearrangements, or THADA gene fusions. In the 2022 5th edition of the WHO Classification, subcentimeter NIFTPs and oncocytic NIFTPs were introduced as new subtypes. In this review, we summarize the epidemiology, ultrasound features, histology/cytology, and molecular characteristics of NIFTP. As research continues to refine diagnostic criteria and management approaches, recognizing the distinct molecular and clinical features of NIFTP is essential for optimizing patient care and ensuring appropriate surgical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.